期刊文献+

大鼠腹腔和静脉给予羟丙基-β-环糊精毒性比较实验研究 被引量:6

Comparative study on toxicity of intravenous and intraperitoneal injection of Hydroxypropyl-β-cyclodextion in rats
原文传递
导出
摘要 目的给大鼠连续iv和ip羟丙基-β-环糊精(HP-β-CD),观察是否产生蓄积毒性反应,确定毒性反应的靶器官及损害程度,并比较在试验剂量下2种给药方式毒性表现的差异。方法给大鼠ipHP-β-CD200mg/kg、iv54mg/kg,连给30d。观察一般状态反应,检测血液学、血液生化学、组织病理学等指标。结果除ip给予HP-β-CD200mg/kg的动物表现出不同程度的腹膜刺激症状外,动物一般状况良好,体质量、进食量、血液学及血液生化学指标均无异常。但组织病理学观察可见,2种给药方式的动物肾脏均出现皮质部分肾小管上皮明显空泡化、细胞肿胀、胞浆呈疏松淡染的圆形空泡状;肺脏均出现肺泡及间隔内有泡沫细胞。结论HP-β-CDip给药剂量为200mg/kg、iv给药剂量为54mg/kg,连给30d,表现出明显的肾脏毒性和肺脏毒性,毒性表现程度无明显差异;ip给药对腹膜有刺激性。 Objective To observe whether continuous iv and ip of hydroxypropyl-β-cyclodextion (HP-β- CD) induces cumulative toxicity and determine the target organ and severity, and to compare the toxicity in the two ways of injection. Methods Rats were daily given HP-β-CD (200 mg/kg) via ip or HP-β-CD (54 rng/kg) via tail iv for 30 d. The general conditions of rats were observed, and parameters of hematology, biochemical and histopathology were measured. Results Rats ip with HP-β-CD (200 mg/kg) showed different peritoneal irritations. Other rats were in good condition, without abnormal parameters in body weight, food intake, hematology and blood biochemistry. However, histopathologic investigation showed that ip and iv of HP-β-CD caused changes in kidney: the marked vacuolization of the renal tubular epithelial in the renal cortex, cell swelling, round vacuolar of the cytoplasm. They also caused changes in lungs: foam cells in the alveolar and the alveolar septum. Conclusion Consecutive ip of HP-β-CD (200 mg/kg) and iv of HP-β-CD (54 mg/kg) for 30 d show obvious nephrotoxicity and pulmonary toxicity. No significant differences appear in the toxicity caused by the two ways of injection ip of HP-β-CD (200 mg/kg) can cause peritoneal irritation in rats.
出处 《现代药物与临床》 CAS 2009年第6期361-364,共4页 Drugs & Clinic
基金 国家科技支撑计划地方重大专项(2007BAQ00162)
关键词 羟丙基-Β-环糊精 静脉注射 腹腔注射 毒性 Hydroxypropyl-β-cyclodextion intravenous injection intraperitoneal injection toxicity
  • 相关文献

参考文献3

  • 1Gould S, Scott R C. 2-Hydroxypropyl -β-cycloclextrin ( HP-13 CD) :a toxicology review[J]. Food Chem Toxicol, 2005,43 (10) : 1451-1459.
  • 2魏农农.羟丙基-β-环糊精作为静脉制剂的增溶剂需要考虑的问题[J/OL].2005,[2006-03-06].http://www.cde.org.cn/page/framelimit.cbs?ResName=dzkw.
  • 3王艳芝,郑甲信,毕殿洲,邓意辉,刘洋,胡玉荣.羟丙基-β-环糊精用于静脉给药的研究概况[J].中国新药杂志,2007,16(13):1010-1014. 被引量:13

二级参考文献28

  • 1李红霞,辛淮生.β-环糊精的化学改性及其在药剂学领域中的应用进展[J].江苏大学学报(医学版),2005,15(3):264-267. 被引量:19
  • 2DEL VALLE EMM. Cyelodextrins and their uses:a review [J]. Process Biochem, 2004,39 ( 9 ) : 1033 - 1046.
  • 3STELLA VJ,RAJEWSKI RA. Cyclodextrins:their future in drug formulation and delivery [ J ]. Pharm Res, 1997,14 (5) :556 - 568.
  • 4CYCLODEX. Hydroxypropyl beta cyclodextrin [EB/OL]. http ://www. cyclodex.com/about.asp? page_id = 4&n = 4.
  • 5SZENTE L,SZEJTLI J. Highly soluble cyclodextrin derivatives: chemistry, properties,and trends in development [ J ]. Adv Drug Deliv Rev,1999,36( 1 ) :17 -28.
  • 6宁波保税区正佳化学有限公司[EB/OL].http://www.pharmnet.com.cn/product/detail/169029.html.
  • 7COUSSEMENT W, VAN CAUTEREN H, VANDENBERGHE J,et al. 1990. Toxicological profile of HP-β-CD in laboratory animals. [ C ]// Duchene,D. Minutes of the 5th International Symposium on Cyclodextrins. Editions de Sante, 1990:522 - 524.
  • 8BREWSTER ME,ESTES KS,BODOR N. An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubiliser, in rats and monkeys [ J ]. Int J Pharm, 1990,59 ( 3 ) :231 - 243.
  • 9GOULD S,SCOTT RC. 2-Hydroxypropyl-β-cyclodextrin( HP-β-CD) : a toxicology review [J]. Food Chem Toxicol, 2005,43 (10) :1451 -1459.
  • 10FRIJLINK W H, EISSENS AC,HEFTING RN,et al. The effect of parenterally administered cyclodextrins on cholesterol levels in the rat[J]. Pharm Res,1991,8(1) :9 -16.

共引文献12

同被引文献62

  • 1李爱群,王洪彪.pH值对补骨脂中补骨脂素和异补骨脂素鼻粘膜吸收的影响[J].中国中西医结合杂志,2000,20(S1):122-123. 被引量:1
  • 2蒋新国,崔景斌,方晓玲,韦阳,奚念朱.药物的鼻粘膜纤毛毒性及评价方法[J].药学学报,1995,30(11):848-853. 被引量:86
  • 3王东方,吴雪萍,干祖望,曹济航.慢性鼻炎鼻腔纤毛输送功能与气虚相关性研究[J].辽宁中医杂志,1996,23(9):392-393. 被引量:11
  • 4Li Q L, Cheng H, Zhu G Q, et al. Gambogenic acid inhibits proliferation of A549 cells through apoptosis- inducing and cell cycle arresting [J]. Biol Pharm Bull, 2010, 33(3): 415-420.
  • 5Zhang J, Wang L, Gao C, et al. Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits [ J ]. J Ocul Pharmacol Ther, 2008, 24 (5): 501-506.
  • 6Hafner V, Czock D, Burhenne J, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration [J]. Antimicrob Agents Chemother, 2010, 54(6) : 2596-2602.
  • 7Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin ( HP-beta- CD): a toxicology review [J]. Food Chem Toxicol, 2005, 43 (10) : 1451-1459.
  • 8Eiden C, Peyriere H, Cociglio M, et at. Adverse effects ofvor/conazole : a- nalysis of the French pharmacovigilance database [ J ]. Ann Pharmacoth- er ,2007,41 (5) :755.
  • 9Miller D D, Cowen E W, Nguyen J C, et al. Melanoma associaled with long - term voriconazole therapy : a new man ifestation of chronic photo- sensitivity[ J]. Arch Dermatol ,2010,146 ( 3 ) : 300.
  • 10Ryan R, Riahi B S, Philip R Cohen M D. Voriconazole - Associated Phototoxicity [ J ]. Dermatology Online Journal, 2011,17 ( 2 ) : 15.

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部